"Are peptides safe?" is the question that brings most people to this subject. It is also a question that cannot be answered honestly with a single word — because "peptides" is not one thing. The word covers everything from a rigorously trialled prescription medicine to an unverified vial bought from a messaging-app vendor. They do not share a safety profile.
Why there is no single answer
The most important thing to understand is that the word "peptide" spans two very different worlds:
Licensed peptide medicines — things like insulin and the GLP-1 drugs — are approved, regulated, and supported by large clinical trials. Their risks are documented precisely because thousands of people were studied under controlled conditions. That doesn't make them risk-free; it makes their risks known.
Research-market peptides — compounds like BPC-157 and TB-500, sold "research use only" — are a different story. Most evidence is from animals, human data is thin or absent, they are not approved for human use, and independent testing repeatedly finds the products are mislabelled or contaminated. Here the risks are not low. They are unknown, which is not the same thing.
The three questions worth asking instead
Rather than "are peptides safe," the book argues the useful questions are: Is this specific compound an approved medicine or an unregulated one? What does the actual human evidence show — not the animal data, not the anecdotes? And is the product itself what the label claims? Those three questions tell you far more than the blanket one ever could.
The honest summary
- "Peptides" spans licensed medicines and unregulated research compounds — not one safety profile.
- Licensed peptide medicines have known, documented risks from large trials.
- Research-market peptides often have unknown risks, thin human data, and product-quality issues.
- The useful question is never "are peptides safe" — it's "which peptide, and what's the actual evidence?"
Look at specific compounds
GLP-1 medicationsLicensed medicines — and the counterfeit market around them BPC-157The most-discussed research peptide — what the evidence shows TB-500Recovery peptide, thin human data, a key distinction the marketing blurs RetatrutideThe frontier triple-agonist — promising data, not yet approvedThe sober bottom line
The honest answer to "are peptides safe" is that safety is a property of a specific compound, in a specific form, from a specific source — not of the whole category. Learning to ask the sharper question is most of what separates an informed decision from a guess. That is what the book is for.
The whole field, soberly explained.
Peptides: A Sober View covers the licensed medicines, the unregulated market, the regulatory landscape and the evidence — 288 pages, fully sourced, no doses, no protocols, no hype.
Get the book — £14.99